It’s time to approach clinical trials with confidence. We have a device designed to consistently and reproducibly deliver your cancer vaccine to the patient’s dermis. 3M Hollow Microstructured Transdermal System (hMTS) is designed to help your biologic formulation break through skin barriers and potentially achieve your clinical objectives.
When it comes to cancer vaccines, drug delivery matters. In fact, trained professionals encounter difficulties with 25% of intradermal injections. Moreover, intradermal delivery may elicit a stronger immune response. For example, it has been shown to be more effective than the intravenous, intramuscular or intranasal delivery for CD8+ CTL priming and activation of T1 helper cells*.
Your form was submitted successfully!
An error has occurred while submitting. Please try again later...
Product in development. Not available for commercial sale.
If you are authorized by your company to electronically sign this agreement on its behalf, please review and complete the following agreement if your company agrees to the terms set forth below. If you are not authorized, please forward a link to this page to the authorized representative.
3M’s Drug Delivery Systems Division (“3M”) is pleased to offer the following representative samples of 3M Hollow Microstructured Transdermal System (hMTS) and published literature (collectively, “the Kit”) to the company on whose behalf this agreement is signed below (the “Recipient”).
The Kit includes
The brands listed above are trademarks of 3M.